bioRxivPharmacology & ToxicologyPreprint
Model Based Safety Ranking Of Opioid Drugs Using Adversity Index
Krishna Asvalayana, Samadhan Ghubade, Sharayu Paranjpe, Anil Gore
Abstract
Annual ADR report counts of opioid drugs are examined to develop a candidate index of overall safety of a drug. Actual counts for various drugs have been sourced from www.vigiaccess.org. A feature found to be common to all drugs considered is that an exponential function adequately describes the pattern of cumulative counts. In the exponential model, the parameter in the exponent (rate constant) is robust and remains the same whether counts are corrected for exposure or not. We propose use of this rate constant as adversity index of a drug. Drugs in use can be ranked by value of adversity index, lower value suggesting safer drug.\n\nKey pointsCumulative total of annual ADR report counts of opioid drugs follows an exponential pattern. Rate constant in the model is independent of volume of use of the drug. Hence it is a suitable index of overall safety.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Quantifying the severity of adverse drug reactions using social media
Adam Lavertu, Tymor Hamamsy, Russ Biagio Altman·bioRxiv·Feb 2, 2021
- Computational Drug Recommendation Approaches toward Safe Polypharmacy
Wen-Hao Chiang, Xia Ning·bioRxiv·Mar 24, 2019
- Improving drug safety predictions by reducing poor analytical practices
S. E. Lazic, D. Williams·bioRxiv·Sep 25, 2020
- Predicting serious rare adverse reactions of novel chemicals
A. Poleksic, L. Xie·bioRxiv·Oct 15, 2017
- drda: An R package for dose-response data analysis
Alina Malyutina, Jing Ping Tang, Alberto Pessia·bioRxiv·Jun 7, 2021
- Higher anhedonia during withdrawal from initial opioid exposure is protective against subsequent opioid self-administration in rats.
Y. Swain, P. Muelken, … A. C. Harris·bioRxiv·Nov 12, 2019